Coloplast AS 2023 AR2
The report highlights Coloplast's performance for the 2022/23 fiscal year, delivering 8% organic revenue growth and a 28% EBIT margin before special items. A key milestone was the acquisition of Kerecis, an innovative company in the biologics wound care segment utilizing fish-skin technology. The company also made progress on its Strive25 sustainability goals, reducing absolute Scope 1 and 2 emissions by 10% compared to the 2018/19 base year and achieving a 75% production waste recycling rate. Additionally, Coloplast initiated the launch of Luja, a new male intermittent catheter with Micro-hole Zone Technology.
Company: Coloplast AS
Sector: Health Care
Country: Denmark
Year: 2023
Type: AR2
Pages: 170
Coloplast AS
Annual Report
The report highlights Coloplast's performance for the 2022/23 fiscal year, delivering 8% organic revenue growth and a 28% EBIT margin before special items. A key milestone was the acquisition of Kerecis, an innovative company in the biologics wound care segment utilizing fish-skin technology. The company also made progress on its Strive25 sustainability goals, reducing absolute Scope 1 and 2 emissions by 10% compared to the 2018/19 base year and achieving a 75% production waste recycling rate. Additionally, Coloplast initiated the launch of Luja, a new male intermittent catheter with Micro-hole Zone Technology.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Oct 1, 2022 - Sep 30, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees